Upadacitinib在生物制剂暴露后溃疡性结肠炎中优于Tofacitinib和Ustekinumab:TRIDENT-UC研究
这项多中心回顾性研究纳入312例既往≥1种先进治疗失败的溃疡性结肠炎患者,比较Upadacitinib、Tofacitinib和Ustekinumab的疗效。主要结局为无激素临床缓解,Upadacitinib在第16周和第52周的无激素临床缓解率及内镜缓解率均高于另外两种药物,且经倾向评分加权后差异仍显著。
要点
- Upadacitinib第16周无激素临床缓解率47.6%,第52周75.0%。
- Upadacitinib内镜缓解率第16周38.1%,第52周56.8%。
- 加权后Upadacitinib无激素临床缓解和内镜缓解的OR均显著优于Tofacitinib和Ustekinumab。
核心结论
- 在既往生物制剂暴露的溃疡性结肠炎患者中,Upadacitinib的疗效优于Tofacitinib和Ustekinumab。
研究设计与样本
- 回顾性多中心研究,纳入9个中心312例既往≥1种先进治疗失败的溃疡性结肠炎患者。
- 患者分为Upadacitinib组(n=103)、Tofacitinib组(n=74)和Ustekinumab组(n=135),评估第16周和第52周结局。
- 采用倾向评分逆概率加权后的多变量逻辑回归分析加权结局。
主要发现
- 第16周和第52周无激素临床缓解率:Upadacitinib组47.6%和75.0%,Tofacitinib组27.0%和52.4%,Ustekinumab组26.7%和53.4%。
- 第16周和第52周内镜缓解率:Upadacitinib组38.1%和56.8%,Tofacitinib组13.2%和32.7%,Ustekinumab组24.6%和22.5%。
- 加权后Upadacitinib对比Tofacitinib的无激素临床缓解OR:第16周2.56(95%CI 1.16-5.64),第52周3.14(95%CI 1.22-8.12)。
- 加权后Upadacitinib对比Ustekinumab的无激素临床缓解OR:第16周3.71(95%CI 1.88-7.29),第52周4.68(95%CI 1.96-11.18)。
- 加权后Upadacitinib对比Tofacitinib的内镜缓解OR:第16周7.44(95%CI 2.09-26.53),第52周3.51(95%CI 1.22-10.12);对比Ustekinumab的内镜缓解OR:第16周3.34(95%CI 1.38-8.09),第52周8.69(95%CI 3.07-24.60)。
临床怎么用
- 对于既往先进治疗失败的溃疡性结肠炎患者,选择Upadacitinib可能获得更高的无激素临床缓解和内镜缓解机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite the progress in advanced therapies (ATs) for ulcerative colitis (UC), selecting a second-line treatment after failure remains challenging. Recent guidelines recommend upadacitinib, tofacitinib, or ustekinumab as high-efficacy options after prior AT failure. However, real-world comparative data among these 3 agents are lacking. METHODS: This was a retrospective multicenter study (9 centers) including patients with UC who failed ≥1 AT. Patients were stratified into upadacitinib, tofacitinib, or ustekinumab groups and assessed at weeks 16 and 52. The primary outcome was steroid-free clinical remission (SFCR), and secondary outcomes included biochemical and endoscopic remission. Weighted outcomes were analyzed using multivariable logistic regression after propensity score-based inverse probability weighting. RESULTS: We evaluated 312 patients (57.1% female [n = 178]; mean age at diagnosis, 32.6 ± 8.4 years) who initiated upadacitinib (n = 103; 33.0%), tofacitinib (n = 74; 23.7%), or ustekinumab (n = 135; 43.3%). The SFCR rates at weeks 16 and 52 were 47.6% and 75.0% for upadacitinib, 27.0% and 52.4% for tofacitinib, and 26.7% and 53.4% for ustekinumab. The corresponding endoscopic remission rates were 38.1% and 56.8%, 13.2% and 32.7%, and 24.6% and 22.5%. After propensity score-based inverse probability weighting, upadacitinib was associated with higher odds of SFCR compared with tofacitinib (week 16: odds ratio [OR], 2.56; 95% confidence interval [CI], 1.16-5.64; week 52: OR, 3.14; 95% CI, 1.22-8.12) and ustekinumab (week 16: OR, 3.71; 95% CI, 1.88-7.29; week 52: OR, 4.68; 95% CI, 1.96-11.18). Upadacitinib outperformed tofacitinib (week 16: OR, 7.44; 95% CI, 2.09-26.53; week 52: OR, 3.51; 95% CI, 1.22-10.12) and ustekinumab (week 16: OR, 3.34; 95% CI, 1.38-8.09; week 52: OR, 8.69; 95% CI, 3.07-24.60) for endoscopic remission at both timepoints. CONCLUSIONS: Upadacitinib showed higher effectiveness than tofacitinib and ustekinumab in bio-experienced patients with UC.
引用
- Camões Neves J, Costa D, Cristiano M, et al. Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study. Clin Gastroenterol Hepatol. 2026. PMID: 42562116. doi:10.1016/j.cgh.2026.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。